• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

个性化医疗的里程碑:从古代到现代——新冠疫情的激发

Milestones in Personalized Medicine: From the Ancient Time to Nowadays-the Provocation of COVID-19.

作者信息

Visvikis-Siest Sophie, Theodoridou Danai, Kontoe Maria-Spyridoula, Kumar Satish, Marschler Michael

机构信息

Université de Lorraine, IGE-PCV, Nancy, France.

The Santorini Conferences (SCs) Association, Nancy, France.

出版信息

Front Genet. 2020 Nov 30;11:569175. doi: 10.3389/fgene.2020.569175. eCollection 2020.

DOI:10.3389/fgene.2020.569175
PMID:33424917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7794000/
Abstract

The first evidence of individual targeting medicine appeared in ancient times thousands of years ago. Various therapeutic approaches have been established since then. However, even nowadays, conventional therapies do not take into consideration individuals' idiosyncrasy and genetic make-up, failing thus to be effective in some cases. Over time, the necessity of a more precise and effective treatment resulted in the development of a scientific field currently known as "personalized medicine." The numerous technological breakthroughs in this field have acknowledged personalized medicine as the next generation of diagnosis and treatment. Although personalized medicine has attracted a lot of attention the last years, there are still several obstacles hindering its application in clinical practice. These limitations have come to light recently, due to the COVID-19 pandemic. This review describes the "journey" of personalized medicine over time, emphasizing on important milestones achieved through time. Starting from the treatment of malaria, as a first more personalized therapeutic approach, it highlights the need of new diagnostic tools and therapeutic regimens based on individuals' genetic background. Furthermore, it aims at raising global awareness regarding the current limitations and the necessity of a personalized strategy to overpass healthcare problems and hence, the current crisis.

摘要

个性化医疗的首个证据出现在数千年前的古代。从那时起,人们建立了各种治疗方法。然而,即使在当今,传统疗法也没有考虑个体的特质和基因构成,因此在某些情况下无法奏效。随着时间的推移,更精确、有效的治疗方法的必要性促使了一个目前被称为“个性化医疗”的科学领域的发展。该领域的众多技术突破使个性化医疗被公认为下一代诊断和治疗方法。尽管个性化医疗在过去几年中受到了广泛关注,但仍有几个障碍阻碍其在临床实践中的应用。由于新冠疫情,这些限制最近才被发现。本综述描述了个性化医疗随时间的“历程”,强调了随着时间推移所取得的重要里程碑。从作为首个更个性化治疗方法的疟疾治疗开始,它强调了基于个体基因背景的新诊断工具和治疗方案的必要性。此外,它旨在提高全球对当前限制以及采用个性化策略以克服医疗保健问题乃至当前危机的必要性的认识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/a048c64ea4fb/fgene-11-569175-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/3dc1f0bfad4d/fgene-11-569175-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/1723fea9fd2a/fgene-11-569175-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/f034a2b3f5fc/fgene-11-569175-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/a048c64ea4fb/fgene-11-569175-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/3dc1f0bfad4d/fgene-11-569175-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/1723fea9fd2a/fgene-11-569175-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/f034a2b3f5fc/fgene-11-569175-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/443d/7794000/a048c64ea4fb/fgene-11-569175-g0004.jpg

相似文献

1
Milestones in Personalized Medicine: From the Ancient Time to Nowadays-the Provocation of COVID-19.个性化医疗的里程碑:从古代到现代——新冠疫情的激发
Front Genet. 2020 Nov 30;11:569175. doi: 10.3389/fgene.2020.569175. eCollection 2020.
2
[The origin of informed consent].[知情同意的起源]
Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27.
3
Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach.中医个性化医学的未来展望:系统生物学方法。
Complement Ther Med. 2012 Feb-Apr;20(1-2):93-9. doi: 10.1016/j.ctim.2011.10.007. Epub 2011 Nov 30.
4
Personalized medicine in breast cancer: pharmacogenomics approaches.乳腺癌的个性化医疗:药物基因组学方法
Pharmgenomics Pers Med. 2019 May 27;12:59-73. doi: 10.2147/PGPM.S167886. eCollection 2019.
5
COVID-19 Pandemic: Implications on Interventional Pain Practice-a Narrative Review.COVID-19 大流行:对介入性疼痛实践的影响——叙事性综述。
Pain Physician. 2020 Aug;23(4S):S311-S318.
6
Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.日本作为超老龄化社会的领跑者:来自日本医学与医疗护理的视角
Geriatr Gerontol Int. 2015 Jun;15(6):673-87. doi: 10.1111/ggi.12450. Epub 2015 Feb 5.
7
Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges.迈向个体化医疗:自身免疫性疾病患者的机遇与挑战。
Immunol Lett. 2017 Oct;190:130-138. doi: 10.1016/j.imlet.2017.08.002. Epub 2017 Aug 8.
8
Will "personalized medicine" need personalized laboratory approach?“个性化医疗”需要个性化的实验室方法吗?
Clin Chim Acta. 2009 Feb;400(1-2):25-9. doi: 10.1016/j.cca.2008.09.029. Epub 2008 Oct 8.
9
Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare.个性化医疗不仅仅是基因组医学:术语混淆阻碍了个性化医疗保健的发展进程。
Per Med. 2012 Jan;9(1):85-91. doi: 10.2217/pme.11.86.
10
Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.个性化医疗的临床应用:一种新范式与挑战。
Curr Pharm Biotechnol. 2017;18(3):194-203. doi: 10.2174/1389201018666170224105600.

引用本文的文献

1
Digital twin for personalized medicine development.用于个性化医疗开发的数字孪生。
Front Digit Health. 2025 Aug 7;7:1583466. doi: 10.3389/fdgth.2025.1583466. eCollection 2025.
2
Personalized Medical Approach in Gastrointestinal Surgical Oncology: Current Trends and Future Perspectives.胃肠外科肿瘤学中的个性化医疗方法:当前趋势与未来展望
J Pers Med. 2025 Apr 27;15(5):175. doi: 10.3390/jpm15050175.
3
Holistic precision wellness: Paving the way for next-generation precision medicine (ngPM) with AI, biomedical informatics, and clinical medicine.

本文引用的文献

1
The network effect: studying COVID-19 pathology with the Human Cell Atlas.网络效应:利用人类细胞图谱研究 COVID-19 病理学。
Nat Rev Mol Cell Biol. 2020 Aug;21(8):415-416. doi: 10.1038/s41580-020-0267-3.
2
Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?血管紧张素转化酶 2(ACE2)基因中的遗传多态性是否在 2019 年冠状病毒病(COVID-19)中起作用?
Clin Chem Lab Med. 2020 Jun 29;58(9):1415-1422. doi: 10.1515/cclm-2020-0727. Print 2020 Aug 27.
3
Genomewide Association Study of Severe Covid-19 with Respiratory Failure.
整体精准健康:借助人工智能、生物医学信息学和临床医学为下一代精准医学(ngPM)铺平道路。
FASEB Bioadv. 2025 Mar 3;7(4):e70005. doi: 10.1096/fba.2024-00198. eCollection 2025 Apr.
4
Digital Health Technologies in Pediatric Infectious Disease and the Perspective of Patients and Healthcare Professionals: A Review.儿科传染病中的数字健康技术以及患者和医疗保健专业人员的观点:综述
Health Sci Rep. 2025 Mar 2;8(3):e70514. doi: 10.1002/hsr2.70514. eCollection 2025 Mar.
5
Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives.变革个性化医疗:与多组学数据生成的协同作用、主要障碍及未来展望
Biomedicines. 2024 Nov 30;12(12):2750. doi: 10.3390/biomedicines12122750.
6
Volumetric printing and non-destructive drug quantification of water-soluble supramolecular hydrogels.水溶性超分子水凝胶的体积打印及非破坏性药物定量分析
Drug Deliv Transl Res. 2025 Jun;15(6):2048-2063. doi: 10.1007/s13346-024-01723-6. Epub 2024 Oct 18.
7
Revolution in malaria detection: unveiling current breakthroughs and tomorrow's possibilities in biomarker innovation.疟疾检测的革命:揭示生物标志物创新的当前突破与未来可能性。
Ann Med Surg (Lond). 2024 Jul 17;86(10):5859-5876. doi: 10.1097/MS9.0000000000002383. eCollection 2024 Oct.
8
Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine.弥合差距:个性化癌症医学实施综述
J Pers Med. 2024 May 24;14(6):561. doi: 10.3390/jpm14060561.
9
The Roadmap toward Personalized Medicine: Challenges and Opportunities.个性化医疗之路:挑战与机遇
J Pers Med. 2024 May 21;14(6):546. doi: 10.3390/jpm14060546.
10
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.推进精准医学:药物研发、临床药理学和个性化医疗中创新的计算机模拟方法综述。
Pharmaceutics. 2024 Feb 27;16(3):332. doi: 10.3390/pharmaceutics16030332.
全基因组关联研究严重新冠肺炎伴呼吸衰竭。
N Engl J Med. 2020 Oct 15;383(16):1522-1534. doi: 10.1056/NEJMoa2020283. Epub 2020 Jun 17.
4
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.氯喹或羟氯喹用于预防2019冠状病毒病。
Lancet Infect Dis. 2020 Oct;20(10):1118. doi: 10.1016/S1473-3099(20)30296-6. Epub 2020 Apr 17.
5
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.阿比多尔单药治疗优于洛匹那韦/利托那韦治疗 COVID-19。
J Infect. 2020 Jul;81(1):e21-e23. doi: 10.1016/j.jinf.2020.03.060. Epub 2020 Apr 10.
6
Lopinavir-ritonavir in severe COVID-19.洛匹那韦-利托那韦治疗重症新型冠状病毒肺炎
Nat Med. 2020 Apr;26(4):465. doi: 10.1038/s41591-020-0849-9.
7
Tocilizumab treatment in COVID-19: A single center experience.托珠单抗治疗 COVID-19:单中心经验。
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
8
Developing antibody tests for SARS-CoV-2.研发针对新型冠状病毒的抗体检测方法。
Lancet. 2020 Apr 4;395(10230):1101-1102. doi: 10.1016/S0140-6736(20)30788-1.
9
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.利巴韦林治疗新型冠状病毒:COVID-19 评估的基础。
J Med Virol. 2020 Jul;92(7):740-746. doi: 10.1002/jmv.25798. Epub 2020 Apr 10.
10
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.